Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%,
2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic
contact dermatitis (ACD).
The purpose of the open label extension is to assess the long-term safety, tolerability, and
efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact
dermatitis.